Thousands of patients treated for Thyroid Eye Disease are reporting irreversible hearing loss. If you were affected, you may be entitled to significant compensation.
Medical Alert: Recent studies show hearing damage from Tepezza may be permanent, contradictory to initial "temporary" claims. 65% of patients in a Stanford study reported hearing issues.
Tepezza (teprotumumab-trbw) was approved in 2020 as the first treatment for Thyroid Eye Disease (TED). While effective for eye symptoms, patients were told auditory side effects were temporary.
However, post-market studies revealed a different reality. The lawsuit alleges that Horizon Therapeutics failed to properly warn patients and doctors about the risk of permanent hearing loss and tinnitus, misrepresenting the drug's safety profile to boost sales.
Patients often experience worsening symptoms after just a few infusions. Common injuries include:
A landmark study by Stanford University found alarming rates of hearing damage in Tepezza users:
Internal analysis suggests the manufacturer knew about higher ototoxicity rates but failed to update safety labels promptly.
Hearing loss affects communication, employment, and mental health. Compensation aims to cover these life-altering impacts.
Costs for hearing aids ($2,000–$7,000+), cochlear implants, ENT visits, and audiology testing.
Damages for social isolation, depression, anxiety, and lost enjoyment of life due to deafness.
Penalties against the manufacturer for concealing known risks from the public.
Estimated Settlements: Severe, permanent hearing loss cases are predicted to reach settlements of $150,000 to $500,000+.
Free & Private Evaluation